Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

Lenvatinib significantly prolonged progression‐free survival (PFS) versus placebo in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) in the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial. This subanalysis evaluated the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyota, Naomi, Schlumberger, Martin, Muro, Kei, Ando, Yuichi, Takahashi, Shunji, Kawai, Yasukazu, Wirth, Lori, Robinson, Bruce, Sherman, Steven, Suzuki, Takuya, Fujino, Katsuki, Gupta, Anubha, Hayato, Seiichi, Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714672/
https://www.ncbi.nlm.nih.gov/pubmed/26426092
http://dx.doi.org/10.1111/cas.12826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714672/
https://www.ncbi.nlm.nih.gov/pubmed/26426092
http://dx.doi.org/10.1111/cas.12826

Ejemplares similares